U.S. Markets closed

Here are Boston-area biotechs pursuing Parkinson's treatments

Allison DeAngelis
Here are Boston-area biotechs pursuing Parkinson's treatments

The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.